LENTIVIRAL VECTOR FOR OVEREXPRESSING EGF, RECOMBINANT STEM CELL, AND USE THEREOF
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Apr 10, 2025
app pub date -
Oct 25, 2024
filing date -
Oct 25, 2024
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The disclosure provides a lentiviral vector for overexpressing Epidermal Growth Factor (EGF), a recombinant stem cell containing the lentiviral vector, and use of the lentiviral vector and the recombinant stem cell containing the lentiviral vector in the preparation of a medicament for the treatment of related diseases. The lentiviral vector of the disclosure comprises a vector plasmid, wherein the vector plasmid comprises a 5′LTR containing a ψ sequence, a 3′LTR, a target gene sequence between the 5′LTR and the 3′LTR, and a promoter sequence and a translation initiation sequence operably linked to the target gene sequence, and the target gene sequence is a nucleotide sequence encoding EGF.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully